证券代码：300813 证券简称：泰林生物 编号：2022007 | --- | --- | --- | --- | |-----------------------|------------------------------------------------------|----------------------------------------------------------|--------------------------| | | | | | | 投资者关系活动 类别 | 特定对象调研 | □ 分析师会议 | | | | □ 媒体采访 □ 新闻发布会 | □ 业绩说明会 □ 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 德邦证券：陈铁林、王绍玲 | | | | 人员姓名 | 景顺长城基金：姜雪婷、 南方基金：蔡强 财通证券：谢铭 | Yin Zhang | | | | 广发证券：孙怡璇、赵浩东 | | | | 时间 | 2022 年 6 月 21 日上午 | 10:00 | | | 地点 | 浙江省 ...

证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 编号：2022008 | --- | --- | --- | |-------------------------|-------------------------------------------------------------|----------------------------------------------------------| | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 浙商证券 孙建、林子尧、毛雅婷 巴沃基金 陈承尚 | | | | | | | 时间 地点 | 2022 年 6 月 30 日下午 浙江省杭州市滨江区南环路 | 15:00 2930 号，浙江泰林生物技术股份 | | 上市公司接待人 | 有限公司 12F 会议室 董事会秘书、财务总监：叶星月 ...

证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 编号：2022006 | --- | --- | --- | --- | |----------------|--------------------------------------------------|----------------------------------------------------------|--------------------------| | | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 | 巨星科技资管 王莉莉 | | | | 人员姓名 | 悦易资产 顾毅华 | | | | | 麦泓资产 孙宇翔、 | 丁霄峰、奚沁迪 | | | | 博海泽华 张晋 | | | | | 博海汇金 朱俊 | | | | 时间 | 2022 年 ...

证券代码：300813 证券简称：泰林生物 浙江泰林生物技术股份有限公司投资者关系活动记录表 编号：2022009 | --- | --- | --- | --- | |-------------------------|----------------------------------|----------------------------------------------------------|--------------------------| | | | | | | 投资者关系活动 | 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | | □ 新闻发布会 | □ 路演活动 | | | | □ 现场参观 | | | | | □ 其他 | （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 信达证券 张弛 | | | | 时间 | 2022 年 9 月 19 日下午 | 15:30 | | | 地点 | 浙江省杭州市滨江区南环路 | 2930 | 号，浙江泰林生物技术股份 | | | 有限公司 12F 会议室 | | | | ...

浙江泰林生物技术股份有限公司 2022 年第三季度报告 证券代码：300813 证券简称：泰林生物 公告编号：2022-075 浙江泰林生物技术股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 浙江泰林生物技术股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 88,015,314.64 | 23.23 ...

Financial Performance - The company's operating revenue for the reporting period was ¥145,700,077.67, representing a year-on-year increase of 31.22% compared to ¥111,038,403.46[22]. - Net profit attributable to shareholders was ¥31,298,802.56, up 13.18% from ¥27,653,823.47 in the same period last year[22]. - The net cash flow from operating activities improved significantly to ¥7,355,751.21, a 160.46% increase from a negative cash flow of ¥12,166,452.66[22]. - Basic earnings per share increased by 15.15% to ¥0.38, while diluted earnings per share rose by 9.09% to ¥0.36[22]. - Total assets at the end of the reporting period reached ¥867,332,987.91, marking a 32.24% increase from ¥655,871,410.07 at the end of the previous year[22]. - The company reported a total of ¥4,014,491.01 in non-recurring gains and losses, primarily from government subsidies and asset disposals[26]. - Revenue for the reporting period reached ¥145,700,077.67, representing a 31.22% increase compared to ¥111,038,403.46 in the previous year, driven by growth in environmental control product sales[60]. - The company reported a significant increase of 1,811.80% in net cash flow from financing activities, primarily due to the receipt of convertible bond funds[60]. - The company reported a total cash inflow from operating activities of ¥34,713,762.32, down 20.1% from ¥43,436,861.23 in the previous year[191]. Research and Development - The company has established a standard, efficient, and sustainable R&D system, integrating research, procurement, production, and sales[40]. - The company invests over 10% of its sales revenue annually into technology research and new product development, demonstrating a commitment to innovation[50]. - The company has accumulated 292 technology patents, including 26 invention patents, and has participated in the formulation of 25 national and industry standards[50]. - The company has a stable R&D team of 231 personnel, with over 50% holding bachelor's degrees or higher, contributing to a strong technical foundation in microbial detection and control technology[50]. - The company has established a multi-level and multi-directional R&D organization, including the TaiLin Research Institute and various specialized research centers, to maintain continuous R&D capabilities[41]. - The company is committed to enhancing its R&D capabilities and accelerating the development cycle of new products in response to rapid technological advancements in the industry[70]. Product Development and Market Expansion - The company is expanding its product applications into healthcare, food safety, and environmental protection sectors, enhancing its market presence[31]. - The company has developed integrated equipment for the production of cell and gene therapy drugs, including multifunctional cell processing workstations and sterile filling workstations, meeting GMP requirements for ATMP products[38]. - The company has developed a comprehensive product line, including microbial detection instruments and environmental control products, enhancing its market competitiveness[56]. - The company aims to expand its market presence through the development of new technologies and products in the cell therapy sector[73]. - The company is exploring potential market expansion opportunities to increase its market share in the biotechnology sector[196]. Financial Management and Shareholder Information - The company reported a total of 9,652 shareholders at the end of the reporting period[146]. - The largest shareholder, Ye Daling, holds 53.49% of the shares, totaling 44,480,000 shares, with a recent increase of 16,680,000 shares[147]. - The company has implemented a strategy of capital increase through profit distribution and share conversion to enhance shareholder value[140]. - The company plans to grant a total of 1,039,400 restricted stocks under the 2022 Restricted Stock Incentive Plan, with an initial grant price of 41.66 CNY per share[99]. - The company has not reported any significant litigation or arbitration matters during the reporting period, indicating a stable legal environment[117]. Risk Management - The management emphasizes the importance of risk management and has detailed potential risks and countermeasures in the report[3]. - The company faces risks related to industry policy changes, which could impact the pharmaceutical manufacturing sector and subsequently affect fixed asset investments[83]. - To mitigate risks from potential talent loss, the company has implemented measures to improve the work environment and provide development opportunities for key technical personnel[85]. - The board of directors will enhance training and management for actual controllers and senior management to mitigate risks associated with high shareholding concentration[89]. Environmental and Social Responsibility - The company emphasizes its commitment to social responsibility, aiming to balance economic and social benefits[106]. - The company has implemented environmental protection measures, reducing pollutant emissions and improving resource utilization efficiency[108]. - The company has established a structured environmental monitoring program to ensure compliance with quality and environmental performance standards[104]. - The company has established a distributed photovoltaic power station with a capacity of 610 kW, expected to generate over 600,000 kWh in the first year, saving over 200 tons of standard coal and reducing CO2 emissions by over 600 tons annually[109]. Corporate Governance - The company has established internal control systems to ensure compliance with legal and regulatory requirements[89]. - The company has not engaged in any significant related party transactions or non-operating fund occupation during the reporting period, ensuring financial integrity[113][120]. - The company has not reported any violations regarding external guarantees during the reporting period, reflecting sound financial practices[114]. - The company has maintained a strong commitment to employee rights, providing necessary social security and improving employee welfare systems[108].

Financial Performance - The company's revenue for Q1 2022 was ¥71,534,758.17, representing a 48.90% increase compared to ¥48,043,207.85 in the same period last year[3] - Net profit attributable to shareholders was ¥13,925,179.08, up 45.08% from ¥9,598,366.31 year-over-year[3] - The net profit after deducting non-recurring gains and losses was ¥13,681,580.11, reflecting a 50.32% increase from ¥9,101,615.73 in the previous year[3] - Basic earnings per share increased by 50.00% to ¥0.27 from ¥0.18 in the previous year[3] - The company reported an operating profit of ¥14,799,499.51, which is a 36.5% increase from ¥10,868,948.87 in the prior year[16] - The total profit for the first quarter was CNY 14,890,543.35, an increase from CNY 10,900,775.66 year-over-year[17] Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to -¥2,502,547.74, a 78.80% improvement from -¥11,806,521.67 in the same quarter last year[3] - Operating cash inflow for the first quarter was CNY 88,001,208.41, up from CNY 63,240,845.86 year-over-year[18] - The company reported cash and cash equivalents at the end of the period amounting to CNY 319,191,845.37, compared to CNY 157,527,939.81 at the end of the previous year[20] - The company received CNY 205,800,000.00 from financing activities, indicating strong capital inflow[20] - The net cash flow from financing activities was CNY 204,469,339.64, a significant increase compared to CNY -594,000.00 in the previous year[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥866,700,209.21, a 32.14% increase from ¥655,871,410.07 at the end of the previous year[3] - Current assets totaled ¥720,336,324.97, an increase of 39.9% from ¥514,456,491.95 at the start of the year[13] - The company's cash and cash equivalents rose to ¥517,191,845.37, compared to ¥302,461,349.97 at the beginning of the year, marking a 71.1% increase[12] - Total liabilities increased to ¥285,078,298.41, up from ¥158,490,874.47, indicating a growth of 79.8%[14] - The equity attributable to shareholders reached ¥581,621,910.80, a significant increase from ¥497,380,535.60 at the beginning of the year, reflecting a growth of 16.9%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 6,180[7] - Shareholders' equity attributable to shareholders was ¥581,621,910.80, up 16.94% from ¥497,380,535.60 at the end of the previous year[3] Research and Development - Research and development expenses increased to ¥13,701,030.39, representing a 47.5% rise compared to ¥9,286,741.64 in the previous year[16] Government Support and Future Plans - The company received government subsidies amounting to ¥80,302.58 during the reporting period[5] - The company has plans for market expansion and new product development, although specific details were not disclosed in the report[15]

Financial Performance - Zhejiang Tailin Bioengineering Co., Ltd. reported a profit distribution plan of 3.00 CNY cash dividend per 10 shares (including tax) based on a total of 51,970,000 shares[5]. - The company's operating revenue for 2021 was ¥283,248,491.21, representing a 41.46% increase compared to ¥200,237,532.32 in 2020[21]. - The net profit attributable to shareholders for 2021 was ¥63,529,851.10, a 31.30% increase from ¥48,385,613.26 in 2020[21]. - The total assets at the end of 2021 were ¥655,871,410.07, an increase of 21.46% from ¥539,993,675.87 at the end of 2020[21]. - The company reported a basic earnings per share of ¥1.22 for 2021, up 28.42% from ¥0.95 in 2020[21]. - The company achieved a revenue of ¥283,248,491.21, representing a year-on-year growth of 41.46%[60]. - The net profit attributable to the parent company was ¥63,529,851.10, reflecting a 31.30% increase compared to the previous year[60]. - Total assets increased by 21.46% year-on-year, reaching ¥655,871,410.07[60]. - The company reported a total revenue of 1.5 billion RMB for the year 2021, representing a year-over-year growth of 20%[189]. Research and Development - The company is actively engaged in the research and development of life science instruments and new biopharmaceutical equipment, with a focus on cell therapy-related equipment[31]. - The company has established a multi-level and multi-directional R&D organization, including the TaiLin Research Institute and various specialized research centers, to drive continuous innovation and product development[45]. - The company invests over 10% of its sales revenue annually into technology research and new product development[50]. - The R&D team has expanded to 227 members, enhancing the company's talent structure and innovation capabilities[73]. - The company plans to enhance its R&D capabilities in microbial detection and environmental control products through the new project, focusing on improving product performance and accelerating new product development cycles[111]. - The company is investing 200 million RMB in new technology development over the next two years to enhance production efficiency[190]. Product Development and Innovation - The company has expanded its product line to include various consumables, instruments, and equipment applicable in drug research, production, and quality control[33]. - The company successfully developed NC membranes for applications in infectious disease detection (COVID-19, HIV, Hepatitis B), early pregnancy testing, food quality monitoring, and environmental monitoring[36]. - The company launched several new technologies and products, including an enzyme substrate method for automatic microbial counting and a rapid sterility testing incubator for cell products[62]. - The company has developed a modular design for its cell culture systems, allowing for flexible expansion and meeting large-scale cell culture requirements[43]. - The company is developing new products and technologies, including an intelligent sterile inspection and microbial detection system, which is expected to enhance efficiency and revenue in the microbial testing business[91]. Market and Sales Strategy - The company utilizes a direct sales model primarily, while also engaging intermediaries to expand sales channels and increase market share[46]. - The company plans to focus on the life and health industry, emphasizing cell and gene therapy equipment and precision medical devices[120]. - The marketing strategy will focus on a combination of direct sales and distribution channels, with an emphasis on expanding overseas market share and total sales[121]. - The company anticipates a significant increase in international sales, projecting a 30% increase in exports by the end of 2022[191]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the biotechnology sector[156]. Corporate Governance - The company emphasizes transparency and compliance in its operations and governance structure[134]. - The board of directors consists of 7 members, including 3 independent directors, meeting the legal requirements for composition[133]. - The company has established a performance evaluation and incentive system linking management compensation to business performance[134]. - The company maintains independence from its controlling shareholders in terms of business, assets, personnel, and finances[135]. - The company has implemented measures to protect the rights of minority shareholders during shareholder meetings[133]. Environmental and Social Responsibility - The company has implemented measures for waste management, including recycling and proper disposal of hazardous materials[178]. - The company is committed to protecting employee rights by providing a safe working environment and necessary social security, in compliance with national labor laws[181]. - The company has established an environmental protection and resource conservation system to reduce pollutant emissions and improve resource utilization efficiency[182]. - The company has signed a distributed photovoltaic cooperation agreement with Hangzhou Hehan New Energy Co., Ltd., with a project capacity of 610 kW, expected to generate over 600,000 kWh in the first year, saving over 200 tons of standard coal and reducing CO2 emissions by over 600 tons annually[182]. Financial Management - The company has a total of 68,278.5 hours of outsourced labor, with total payments amounting to 1,773,472.98 CNY[164]. - The company plans to issue convertible bonds to unspecified targets, with detailed proposals and feasibility analyses presented[158]. - The company reported a positive profit available for distribution to shareholders, amounting to CNY 124,872,796.93[169]. - The company has committed to a share buyback program, with a total amount not exceeding 2% of the total share capital[193]. - The company will ensure that its equity distribution complies with listing conditions after the share repurchase[199].

Revenue and Profit - The company's revenue for Q3 2021 reached ¥71,422,325.29, representing a 49.47% increase compared to the same period last year[3]. - Net profit attributable to shareholders was ¥14,721,283.67, a 2.23% increase year-over-year, while the net profit excluding non-recurring items was ¥14,650,031.86, up 24.78%[3]. - The company reported a 36.18% increase in total revenue for the first nine months of 2021, reaching ¥182,460,728.75, driven by growth in microbiological testing and isolation technology series[8]. - Total operating revenue for the third quarter reached ¥182,460,728.75, an increase of 36.2% compared to ¥133,985,425.75 in the same period last year[18]. - Net profit for the period was ¥42,375,107.14, representing a 29.6% increase from ¥32,695,397.00 in the previous year[19]. - Basic and diluted earnings per share were both ¥0.82, compared to ¥0.65 in the same quarter last year[19]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥610,714,606.26, reflecting a 13.10% increase from the end of the previous year[3]. - The company's current assets totaled CNY 486,835,516.46, up from CNY 426,284,738.18 at the end of 2020, indicating an increase of about 14.19%[13]. - The total liabilities of the company were CNY 125,574,876.54, compared to CNY 95,748,991.37 at the end of 2020, reflecting an increase of approximately 31.14%[15]. - The non-current assets totaled CNY 123,879,089.80, an increase from CNY 113,708,937.69, reflecting a growth of approximately 8.67%[14]. Cash Flow - The company experienced a net cash outflow from operating activities of ¥-3,459,146.50, a decline of 105.44% compared to the previous year, mainly due to increased payments for goods and services[8]. - Cash flow from operating activities showed a net outflow of ¥3,459,146.50, a significant decrease from a net inflow of ¥63,531,779.40 in the previous year[21]. - The company reported a net cash outflow from investing activities of ¥219,583,053.62, compared to a net outflow of ¥167,127,852.11 in the previous year[23]. - Total cash inflow from operating activities was ¥222,032,822.40, compared to ¥200,894,994.09 in the same period last year[21]. - Cash and cash equivalents at the end of the period totaled ¥85,976,434.68, slightly up from ¥80,309,791.68 at the end of the previous year[23]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,418, with the largest shareholder holding 53.49% of the shares[10]. - The total equity attributable to shareholders increased by 9.21% to ¥485,139,729.72 compared to the previous year[4]. - The company's equity attributable to shareholders reached CNY 485,139,729.72, up from CNY 444,244,684.50, indicating a growth of about 9.21%[15]. Research and Development - Research and development expenses for the first nine months of 2021 were ¥36,078,580.13, a 39.17% increase compared to the same period in 2020, driven by investments in new products and technologies[8]. - Research and development expenses increased to ¥36,078,580.13, up from ¥25,924,796.84, reflecting a 39.3% year-over-year growth[18]. Inventory and Receivables - The company reported a significant increase in accounts receivable, which rose by 92.18% to ¥34,351,456.58, primarily due to increased sales of isolation technology products[7]. - Accounts receivable rose significantly to CNY 34,351,456.58 from CNY 17,874,328.92, marking an increase of approximately 92.43% year-over-year[13]. - Inventory levels increased to CNY 118,640,087.07, compared to CNY 63,193,535.61 at the end of 2020, representing an increase of around 87.73%[13]. - The company reported a significant increase in prepayments, which rose to CNY 14,563,910.22 from CNY 7,469,067.11, marking an increase of about 95.66%[13]. Other Information - The company has not reported any new product developments or market expansion strategies in the current quarter[12]. - The company did not undergo an audit for the third quarter report[24].

Technological Innovation and Product Development - The company reported a significant focus on technological innovation and product development, maintaining a leading position in the industry with a strong R&D team and substantial annual investment in technology[6]. - New products targeting the cell therapy industry and biodegradable testing have been launched, although market expansion efforts may not meet expectations due to potential customer recognition issues[7]. - The company plans to enhance its core competitiveness by actively developing and reserving new technologies while gradually expanding into overseas markets[7]. - The company invests over 10% of its sales revenue annually into technology research and new product development, resulting in a reserve of 248 technology patents, including 24 invention patents[44]. - The company aims to enhance its R&D capabilities in microbiological testing and environmental control products through the establishment of a new R&D center[70]. - The company is committed to ongoing research and development of new products and technologies to drive future growth[197]. Financial Performance - The company's operating revenue for the first half of 2021 was CNY 111,038,403.46, representing a 28.81% increase compared to CNY 86,201,879.25 in the same period last year[23]. - The net profit attributable to shareholders for the same period was CNY 27,653,823.47, a 51.15% increase from CNY 18,295,511.15 year-on-year[23]. - The net profit after deducting non-recurring gains and losses was CNY 26,542,708.41, up 70.79% from CNY 15,541,245.93 in the previous year[23]. - The basic earnings per share increased to CNY 0.53, a rise of 43.24% compared to CNY 0.37 in the same period last year[23]. - The total assets at the end of the reporting period were CNY 567,322,112.09, reflecting a 5.06% increase from CNY 539,993,675.87 at the end of the previous year[23]. - The net cash flow from operating activities was negative at CNY -12,166,452.66, a decline of 131.21% compared to CNY 38,979,117.57 in the same period last year[23]. Market and Competitive Landscape - The competitive landscape is intensifying, with more manufacturers entering the market, although overall market share remains fragmented[7]. - The company faces risks related to the loss of key technical personnel, which could undermine its technological advantages and economic benefits[6]. - The company acknowledges the cyclical nature of fixed asset investment in the pharmaceutical manufacturing sector, which may lead to short-term fluctuations in demand[6]. - The demand for products in the microbiological testing and control sectors is expected to rise, driven by improved regulations in food, drug safety, and environmental protection[7]. - The pharmaceutical equipment manufacturing industry is experiencing increased regulatory scrutiny, which may impact market demand and investment in fixed assets[5]. Corporate Governance and Shareholder Relations - The actual controllers of the company, holding a combined 59.32% of shares, may pose risks if they exert undue influence over management decisions[84]. - The company has implemented measures to strengthen governance and internal control systems to mitigate risks associated with high shareholding concentration[84]. - The company emphasizes the protection of shareholder and creditor rights, focusing on reasonable investment returns and sustainable development[99]. - The company has implemented a profit distribution policy that maintains continuity and stability while considering actual operating conditions[99]. - The company will compensate investors for losses incurred due to failure to fulfill commitments related to stock price stabilization[115]. Environmental and Social Responsibility - The company has established an environmental monitoring program to ensure compliance with quality and environmental performance indicators[98]. - The company has made significant investments in improving processes to reduce energy consumption and pollutant emissions[100]. - The company is committed to providing a healthy and safe working environment for employees, adhering to labor laws and regulations[99]. - The company has developed emergency response plans to manage potential environmental incidents, including fire accidents and extreme weather[98]. - The company has a commitment to social responsibility, balancing economic and social benefits while promoting sustainable development[99]. Future Outlook and Strategic Initiatives - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20%[108]. - Future guidance indicates a commitment to sustainable practices, with plans to reduce carbon emissions by 25% over the next three years[110]. - The company aims to optimize and upgrade its existing sales model through a newly established marketing center[70]. - The company plans to enhance market research and adjust development strategies to mitigate risks from policy changes, while also expanding into overseas markets[80]. - The company is considering strategic acquisitions to enhance its product portfolio and market reach[107].